Santarus expects more Zegerid approvals
This article was originally published in The Tan Sheet
Other markets will approve the proton pump inhibitor in 2010, predicts Santarus CEO Gerald Proehl. "We may start to see some modest royalties in the last part of 2010 and into 2011" from GlaxoSmithKline, Proehl said Dec. 15 at the Lippert/Heilshorn Life Sciences Virtual Conference. GSK licenses Zegerid (omeprazole/sodium bicarbonate) in 114 countries in Africa, Asia, the Middle East and Central and South America (1"The Tan Sheet" June 2, 2008). Santarus licensed Rx and OTC Zegerid in Europe to U.K. pharma Norgine in October. Proehl said he also anticipates sales milestone payments as Merck/Schering-Plough introduces Zegerid OTC in U.S. in the first half of 2010 (2"The Tan Sheet" Dec. 7, 2009)
You may also be interested in...
Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor
Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss
Biodiversity footprinting may still be a new concept for pharmaceutical companies, but they need to put a clear supply chain strategy in place now, particularly as the COP 15 conference in December is expected to discuss mandatory reporting of biodiversity risks, says Luka Brown.